Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7245829 | 0.87 | ACKR3 (0.38) | KDM4EACKR3FNTAFNTB | |
| SCHEMBL6634720 | 0.72 | FNTA (0.40) | KDM4EACKR3FNTAFNTB | |
| SCHEMBL3500565 | 0.68 | FNTA (0.33) | FNTAFNTB | |
| SCHEMBL7245699 | 0.67 | KDM4E (0.40) | KDM4EACKR3FNTAFNTBDRD3 | |
| SCHEMBL12405631 | 0.66 | MAPT (0.53) | MAPTTP53KDM4EGFERTDP1 | |
| SCHEMBL3499254 | 0.65 | FNTA (0.43) | MAPTKDM4EACKR3LMNAFNTA | |
| SCHEMBL12404770 | 0.65 | MAPT (0.46) | MAPTTP53KDM4EGFERTDP1 | |
| SCHEMBL3501412 | 0.65 | FNTA (0.74) | LMNAFNTAFNTB | |
| SCHEMBL12360033 | 0.65 | EPHX2 (0.45) | MAPTLMNA | |
| SCHEMBL12359901 | 0.65 | TSHR (0.44) | MAPTTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624157-B2 | Antitumor agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | claimed |
| US-20010039273-A1 | Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase | DING CHARLES Z (US) | 2001-11-08 | — | — | US | claimed |
| EP-0918771-A4 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2001-02-07 | — | — | EP | claimed |
| EP-0918771-A1 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-02 | — | — | EP | claimed |
| WO-1998002436-A1 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-01-22 | — | — | WO | claimed |
| US-6624157-B2 | Antitumor agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20010039273-A1 | Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase | DING CHARLES Z (US) | 2001-11-08 | — | — | US | disclosed |
| EP-0918771-A4 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-0918771-A1 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998002436-A1 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039273-A1 | Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase | CBR1, CBR3, FNTB | MAPT 4563/4885TP53 1154/4885ITGB3 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.